Episodes
Integrating IV Iron into Cancer Care: An Expert Overview of Best Practices
6/11/2025
Host: Brian P. McDonough, MD, FAAFP
Guest: George M. Rodgers, MD, PhD
Guest: Patricia A. Ford, MD
Designed as a dynamic, intensive, and innovative web-based activity, this session will take learners on an in-depth exploration of cancer-related anemia (CRA) and chemotherapy-induced anemia (CIA) as disease states of vast clinical significance, emphasizing the robust prevalence, pathophysiology, and patient burden of CRA/CIA, as well as the prominent role of iron deficiency (ID) in their pathogenesis. Built upon on this foundation, expert faculty will guide attendees through a succinct but comprehensive review of the IV iron evidentiary base in CRA/CIA, including clinical trials, systematic reviews and meta-analyses, and the latest expert consensus guideline recommendations from the NCCN, ASCO/ASH, and ESMO. Practical clinical pearls for safely and effectively implementing IV iron into the real-world hematology/oncology clinic will be emphasized.
Duration:00:22:44
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
5/23/2025
Guest: Neal Shore, MD, FACS
Guest: Sarah Psutka, MD, MS
This online CME program features expert discussions on new research presented at AUA 2025. Drs. Neal Shore and Sarah Psutka explore emerging data on treatment strategies for high-risk BCG-naïve and BCG-unresponsive non–muscle invasive bladder cancer (NMIBC). They also highlight advances in biomarker-directed therapies, including investigational agents targeting HER2 and FGFR alterations. The program emphasizes the clinical relevance and practical application of these findings, offering clinicians actionable insights on evolving bladder cancer care.
Duration:00:16:12
Advancing Care in Non-Clear Cell RCC: Optimizing ICI and TKIs
5/9/2025
Guest: Pedro Barata, MD, MSc, FACP
Guest: Sumanta K. Pal, MD, FASCO
Stay at the forefront of nccRCC care by exploring the latest advances in treatment strategies. Gain key insights into optimizing patient selection, enhancing diagnostic accuracy, and managing adverse events to improve patient outcomes. This comprehensive activity delves into emerging data, the rationale for ICI/TKI combination therapy, the latest clinical trial findings, and best practices for treatment sequencing. Take action today to refine your approach and deliver the best possible care for your patients.
Duration:00:44:24
Considering the Promise of New and Emerging Treatments for Hemophilia: The Need for ITI?
4/30/2025
Host: Stephanie Ambrose, DO
Guest: Jenny McDaniel, MD
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
Duration:00:07:44
Evaluating Emerging Treatment Options: Rebalancing Therapies
4/30/2025
Host: Stephanie Ambrose, DO
Guest: Jenny McDaniel, MD
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
Duration:00:05:59
Multidisciplinary Team Collaboration in the New Era of Hemophilia Treatment
4/30/2025
Host: Jenny McDaniel, MD
Guest: Stephanie Ambrose, DO
Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.
Duration:00:04:15
